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Abstract
Background:  Transcription factors are frequently involved in the process of cellular
transformation, and many malignancies are characterized by a distinct genetic event affecting a
specific transcription factor. This probably reflects a tissue specific ability of transcription factors
to contribute to the generation of cancer but very little is known about the precise mechanisms
that governs these restricted effects.
Methods: To investigate this selectivity in target gene activation we compared the overall gene
expression patterns by micro-array analysis and expression of target genes for the transcription
factor EBF in lymphoma and neuroblastoma cells by RT-PCR. The presence of transcription factors
in the different model cell lines was further investigated by EMSA analysis.
Results: In pre-B cells mb-1 and CD19 are regulate by EBF-1 in collaboration with Pax-5 and E-
proteins. We here show that neuroblastoma cells express these three, for B cell development
crucial transcription factors, but nevertheless fail to express detectable levels of their known target
genes. Expression of mb-1 could, however, be induced in neuroblastoma cells after disruption of
the chromatin structure by treatment with 5-azacytidine and Trichostatin A.
Conclusion: These data suggest that transcription factors are able to selectively activate target
genes in different tissues and that chromatin structure plays a key role in the regulation of this
activity.
Background
The complex process of tumor development often
involves changes in the transcription regulatory networks.
In human cancer, genetic changes involving the transcrip-
tion factor p53 gene is particularly common and the gene
is found mutated in cancers originating from numerous
cell types. This factor is, however, broadly expressed and
directly involved in cell cycle regulation and apoptosis
explaining the common involvement of the protein in
tumor development. Many malignancies are characterized
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by specific chromosomal translocations that frequently
affects the expression or structure of transcription factors
with a more tissue specific expression pattern, often with
an important function during development [1]. Examples
of this can be found within the hematopoetic system
where for instance translocations of Tal-1  is associated
with T cell leukemia's [2] while modified BCL-6 [3] or c-
myc [4] is associated with B cell non-Hodgkin's lympho-
mas. The close correlation with a specific tumor type and
pathology to a specific transcription factor modification
could well be explained by differential expression patterns
and accessibility of the gene for translocation events.
Another possibility could be that the action of the tran-
scription factor is context dependent and therefore the
ability of the modified protein to contribute to tumor
development depends on the cell in which it arises.
To investigate mechanisms involved in lineage specific
gene regulation and transcription factor target gene selec-
tion in tumor cells we have compared transcription factor
expression in neuroblastoma and pre-B lymphoma cells.
This revealed that both these highly divergent tumor types
expressed the transcription factor EBF [5] that has been
contributed a central role in B cell development [6]. The
protein is a helix-loop-helix family member [7,8] essential
for B-lymphopoesis in mice [6] where it has been shown
to regulate a large number of pre-B cell restricted genes
including the surrogate light chains [9], CD19 [10] and
the signal transduction proteins Igα (mb-1) [7,11] and Igβ
(B29) [12]. The EBF-1 protein is highly conserved between
human and mouse [13] and it also appears as if the target
gene spectra has been conserved between species even
though the primary promoter sequences of these genes
has diverged [13,14]. Pre-B cells express exclusively EBF-1
[15] while neuroblastoma cells express other family mem-
bers including EBF-2 and -3 [5]. There are limited infor-
mation about EBF target genes in neuroblastoma cells but
binding sites for EBF proteins were identified in the pro-
moters controlling the expression of the neuron restricted
Chromogranin A (CGA) and SCG10 genes [5].
In the present study we were interested in the mechanisms
of tissue specific target gene activation by comparing tran-
scription factor function and gene expression patterns in
neuroblastomas and pre-B cells. We here report that even
though neuroblastoma cells express both Pax-5 and E-
proteins, both suggested to be crucial co-activators for EBF
target genes in pre-B cells, the cells do not express the pre-
B cell restricted target genes mb-1 and CD19. The expres-
sion of the mb-1 gene could, however, be activated by
treatment of the neuroblastoma cells with chromatin dis-
rupting agents. This suggests that chromatin structure is a
key component in the regulation of transcription factor
function, by restricting the accessibility of target genes,
possibly contributing to the apparent link between a tran-
scription factor and specific malignancies.
Methods
Cell culture
HeLa, THP-1, KM3 and Nalm6 cells were grown in RPMI
1640 medium supplemented with 7.5% fetal calf serum
(FCS), 10 mM HEPES, 2 mM pyruvate and 50 µg/ml gen-
tamicin (complete RPMI media) (Life Technologies) at
37°C and 5% CO2. SH-SY5Y, IMR-32 and SK-N-BE(2)c
neuroblastoma cells were cultured in Eagle's Minimum
Essential Medium (MEM) with 10% FCS, 100 U/ml peni-
cillin and 100 µg/ml streptomycin in an atmosphere of
5% CO2 at 37°C (Life Technologies). KCN-69n and LA-N-
1 neuroblastoma cells were cultured in RPMI 1640
medium supplemented with FCS and antibiotics as above.
The SK-N-BE(2)c cells were differentiated with 10 µM all-
trans-retinoic acid (RA) in MEM containing 10% FCS for
0, 2, 8, 24, and 96 hours. 5-azacytidine (5-azaC) treat-
ments were performed on SK-N-BE(2)c and SH-SY5Y cells
at a concentration of 400 nM. After 64 h, fresh medium
containing 50 nM Trichostatin A (TSA) was added. The
cells were harvested in PBS after 24 h.
RT-PCR analysis
RNA was prepared from cells using Trizol (Life Technol-
ogy) and cDNA was generated by annealing 1 µg of total
RNA to 0,5 µg of random hexamers in 10 µl DEPC-treated
water. Reverse transcriptase reactions were performed
with 200 units of SuperScript Reverse Transcriptase (Life
Technologies) in the manufacturers' buffer supplemented
with 0,5 mM dNTP, 10 mM DTT and 20 units RNase
inhibitor (Boeringer Mannheim, Bromma, Sweden) in a
total volume of 20 µl, at 37°C for 1 hr. One-twentieth of
the RT reactions were used in the PCR assays. PCR reac-
tions were performed with 1 unit of Taq-polymerase (Life
Technologies) in the manufacturers' buffer supplemented
with 0.2 mM dNTP, in a total volume of 25 µl. GADPH
was amplified by 25 cycles (94°C, 30 s, 55°C, 30 s and
72°C, 30 s) while 30 cycles were used to amplify CGA,
SCG10, mb-1 and CD19 message (94°C, 30 s, 61°C, 30 s,
72°C 30 s). Primers were added to a final concentration
of 1 mM. PCR products were blotted onto Hybond N+
nylon membranes (Amersham) using capillary blotting
with 0.4 M NaOH. Membranes were pre-hybridized in 5X
Denhardt's, 6XSSC, 0.1% SDS and 50 µg/ml Salmon
Sperm DNA, at 57°C for 90 minutes and hybridized with
γ[32P] labeled oligonucleotide for 12 hours at 57°C in the
same solution. Membranes were washed at room temper-
ature 2 times in 2XSSC supplemented with 0.1% SDS for
15 minutes.
Oligonucleotides used for RT-PCR were:
GADPH sense; 5'-CCACCCATGGCAAATTCCATGGCA;BMC Cancer 2004, 4:80 http://www.biomedcentral.com/1471-2407/4/80
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GADPH  antisense; 5'-TCTAGACGGCAGGTCAGGTC-
CACC;
CGA sense: 5'-GAAGATGAACTCTCAGAGGTTC
CGA antisense: 5'-GGATCTCCTTGTAGCCAAGGCTCG
CD19 sense: 5'-AGTCATTGCTGAGCCTAGAGCTG
CD19 antisense: 5'-CTCGGAGTCCTCCTCACTGTCAG
mb-1 sense; 5'-CCAGCATCATTGATGGTGAGCC
mb-1 antisense: 5'-GACATCTCCTATGTTGAGGCTGC
mb-1  hybridization; 5'-CCCGCACAATAGCAG-
CAACAACGCCAACGT
SCG10 sense; 5'-ATGCTGTCACTGATCTGCTCTTGC
SCG10 antisense; 5'-CAGGTTGAACTGTCTGGCTGAAG
EMSA
DNA probes were labeled with γ[32P] ATP by incubation
with T4 polynucleotide kinase (Roche Molecular Bio-
chemicals), annealed and purified on a 5% polyacryla-
mide Tris-borate-EDTA (TBE) gel. Nuclear extract [16], or
in vitro transcribed-translated protein, was incubated with
labeled probe (20,000 cpm, 3 fmol) for 30 min at room
temperature in binding buffer (10 mM HEPES pH [7.9],
70 mM KCl, 1 mM Dithiothreitol, 1 mM EDTA, 2.5 mM
MgCl2, 1 mM ZnCl2, 5% Glycerol) with 0.75 µg Poly(dI/
dC) (Amersham Pharmacia). Antibodies (anti Pax-5 SC-
1974, anti Pu.1 SC-352, anti actin SC-1616, ets1/2 SC-275
and anti myc SC-764 all from Santa Cruz Biotech and anti
E2-2 from Pharmingen) were added 10 min before the
addition of the DNA probe. The samples were separated
on a 6% polyacrylamide TBE gel, which was dried and
subjected to autoradiography.
Oligonucleotides used for EMSA were the following:
mb-1 sense 5'-AGCCACCTCTCAGGGGAATTGTGG;
mb-1 antisense 5'-CCACAATTCCCCTGAGAGGTGGCT;
CD19-BSAP sense 5'-GCAGACACCCATGGTTGAGT-
GCCCTCCAGG;
CD19-BSAP antisense 5'-CCTGGAGGGCACTCAACCAT-
GGGTGTCTGC;
µE5 sense: 5'-GGCCAGAACACCTGCAGACG;
µE5 antisense: 5'-CGTCTGCAGGTGTTCTGGCC;
Oct binding site sense 5'-CATCTCAAGTGATTTGCATCG-
CATGAGACG;
Oct binding site antisense 5'-CGTCTCATGCGATGCAAAT-
CACTTGAGATC;
Lambda B (Pu.1 site) sense: 5'-GAAAAAGAGAAATAAAAG-
GAAGTGAAACCA AG;
Lambda B antisense: 5'-CTTGGTTTCACTTCCTTTTATT-
TCTCTTTTTC;
CRE (ATF5 site) sense: TCA TGG TAA AAA TGA CGT CAT
GGT AAT TA
CRE antisense: TAA TTA CCA TGA CGT CAT TTT TAC CAT
GA
Pre-B cells and Neuroblastoma cells display similarities in  overall gene expression patterns Figure 1
Pre-B cells and Neuroblastoma cells display similarities in 
overall gene expression patterns. The figure shows a hierar-
chical tree based on cDNA micro-array analysis of the 
expression of 2162 genes in a set of cell lines as indicated. 
Each individual hybridization experiment is represented by 
the name of the cell line and the number of the experiment. 
THP-1 is a human myeloma cell line, HeLa a human epithelial 
cell line, Nalm6 and KM3 represents human pre-B lym-
phoma. SY represents the neuroblastoma cell line SH-SY5Y 
and SK the neuroblastoma cell line SK-N-BE(2)c.
Myeloid leukemia
Epithelial cells
Pre-B lymphoma
Pre-B lymphoma
Neuroblastoma
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cDNA micro-array analysis
RNA from Nalm6, SK-N-BE(2)c, SH-SY5Y, KM3, THP-1
and HeLa cells was extracted using Trizol™ (Invitrogen,
Carlsbad, California). A common RNA control obtained
by mixing a variety of cell lines was used for all hybridiza-
tions. RNA was concentrated to 50 µg total RNA (25 µg
sample RNA and 25 µg control RNA) to generate ami-
noallyl-modified cDNA. Sample cDNA was labeled with
Cy3-dCTP and control RNA was labeled with Cy5-dCTP
using CyScribe Post-Labeling Kit (Amersham Pharmacia
Biosciences). A hybridization solution was made by com-
bining labeled cDNA with 20 µl Cot-1 DNA (1 mg/ml), 3
µl Poly dA (4 mg/ml) and 1.5 µl yeast t-RNA (4 mg/ml),
dry down by speed-vac and resuspended in 40 µl Pronto!
Universal Hybridization Solution™ (Pronto!™ Universal
Microarray Reagent System, Corning). The hybridization
solution was added to a pre-hybridized microarray slide
(DNA microarrays were obtained from the SWEGENE
DNA Microarray Resource Center, Lund University). The
arrays were hybridized at 42°C for 18 hrs, washed accord-
ing to the manufacturers recommendations (Pronto!™
Universal Microarray Reagent System, Corning), dried by
centrifugation and scanned on Agilent microarray scan-
ner. Scans were analyzed using GenePix Pro versions
4.0.1.9 and 4.1.1.4. BioArray Software Environment
(BASE) (Saal et al. Genome Biology 2002,
3(8):software0003.1–0003.6). The settings for the analy-
sis presented were, Background Correlation: Mean FG –
Mean BG, Spot filter: (Raw) SNR ch1 mean > = 2, (Raw)
SNR ch2 mean > = 2, (Raw) Flags = 0, (Raw) Spot diame-
ter > = 40, Normalization: Lowess, Reporter filter: in # of
assays = 16, Analysis: Hierarchical clustering (reporter)
Results
Neuroblastoma and lymphoma cell lines display 
similarities in overall gene expression patterns but not of 
known EBF target genes
Knowing that neuroblastoma and pre-B cells share the
expression of EBF [5,13,14], we wanted to investigate the
potential similarities in overall gene expression patters in
these two types of tumor cells. To this end we used cDNA
micro-array analysis with material from two pre-B cell
lines (Nalm6 and KM3), one EBF high and one EBF low
expressing neuroblastoma cell line (SK-N-BE(2)c and SH-
SY5Y) [5] (Data not shown, 13) one epithelial cell line
(HeLa) and one myeloid cell line (THP-1). The level of
specific mRNAs in the samples were compared to that
obtained by a pooled reference RNA on cDNA gene chip
(Appendix A). This allowed us to reliably investigate vari-
ations in expression of 2 162 genes in our cell lines and to
group the different samples based on overall similarity in
gene expression patterns (Figure 1). This suggested that
the pre-B and neuroblastoma cell lines clustered to the
same half of the expression tree even though THP-1 is a
hematopoetic cell line. It also appeared as if while the two
pre-B cell lines were rather similar the two neuroblastoma
lines displayed larger discrepancies in overall expression
patterns. It should be noted that the SK-N-BE(2)c cell line
carries an amplified N-myc gene, which in the clinic is cor-
related to adverse outcome of the disease, while the SH-
SY5Y cell line carry an N-myc gene in germ line configura-
tion [18].
The finding that these two different types of tumors did
display a degree of similarity in overall gene expression
patterns opened the possibility that the previously identi-
fied EBF target genes would be expressed in both cell
types. To investigate this possibility we extracted RNA
from pre-B cell lines as well as neuroblastoma cells and
investigated the expression of the pre-B cell EBF target
genes CD19 [19] and mb-1 [13] as well as the potential
neuroblastoma EBF target genes SCG10 and CGA [5] by
RT-PCR (Figure 2). This indicated that while the neurob-
lastoma cells expressed SCG10 and CGA message they did
not express either CD19 or mb-1 message. The opposite
pattern was observed in the pre-B cell lines where CD19
and  mb-1  but not SCG10  or  CGA  message could be
detected. This show that even though neuroblastoma and
pre-B lymphoma cells to some extent share gene expres-
sion patterns, they do not appear to share the expression
of specific EBF target genes.
Neuroblastoma and pre-B lymphoma cells share the 
expression of the transcription factor Pax-5
Previous work has shown that both the mb-1 and CD19
genes are genetic targets for both EBF and the paired
domain protein Pax-5 (BSAP) [13,19-21]. Thus, one pos-
sibility to explain lineage-restricted expression of these
genes could be selective expression of Pax-5 in the Pre-B
cells. To investigate this possibility we performed EMSA
analysis with nuclear extracts from two human pre-B cell
lines (Nalm6 and KM3) and two neuroblastoma cell lines
(SH-SY5Y and SK-BE(2)c) (Figure 3A). As probes we used
a consensus Oct binding site and the Pax-5 binding site
from the human CD19 promoter [20]. These experiments
revealed that not only the pre-B cell lines, but also the
neuroblastoma cell lines expressed proteins able to inter-
act with the CD19 Pax-5 binding site. No such binding
activity was detected in extracts from epithelial cells (Data
not shown). To verify that the binding activity was due to
the presence of Pax-5 we performed a super-shift experi-
ment using a Pax-5 specific antibody, a control antibody
or no antibody in the binding reaction (Figure 4). While
the control antibody did not affect formation of the com-
plex the Pax-5 antibody resulted in a reduced DNA bind-
ing and also the appearance of a weak super-shifted band
using either pre-B (Data not shown) or neuroblastoma
nuclear extracts. These data confirmed that the DNA/pro-
tein complex observed in extracts from the neuroblastoma
cells was composed of Pax-5 protein. Pax-5 protein couldBMC Cancer 2004, 4:80 http://www.biomedcentral.com/1471-2407/4/80
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also be detected in the neuroblastoma cell lines IMR-32,
KCN-69n and LA-N-1 (Figure 4). Since the binding activ-
ity of several transcriptions factors such as E-proteins and
EBF appear to be modulated during the induced differen-
tiation of neuroblastoma cells [5,22-24] we wanted to
investigate if this was the case also for Pax-5. To this end,
EBF target genes are expressed in a tissue specific manner Figure 2
EBF target genes are expressed in a tissue specific manner. The figure show ethidium bromide stained agarose gels with the 
products from RT-PCR analysis of Nalm6, KM3, SH-SY5Y and SK-N-BE(2)c cells. The panel shows the expression of actin, SCG 
10, CGA, mb-1 and CD19 mRNA as indicated. Serial dilutions using 1, 1/5 and 1/25 of the template cDNA after 25 (actin) and 30 
(SCG 10, CGA, mb-1 and CD19) cycles of PCR were used.
Control (actin)
SCG 10
CGA
Mb-1
Cd19
Nalm6 KM3 SH-SY5Y SK-N-BE(2)c
-RT -RT -RT -RTBMC Cancer 2004, 4:80 http://www.biomedcentral.com/1471-2407/4/80
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SK-BE(2)c cells were treated with retinoic acid and pro-
teins were extracted at 2, 8, 24, 48, 72 and 96 hours after
stimulation. The induction of differentiation was assayed
by morphological change and dendrite outgrowth of the
stimulated cells. We then analyzed the amount of Oct pro-
tein as well as of Pax-5 proteins at the different time points
after stimulation by EMSA (Figure 4). This indicated that
by using the octamer binding activity as a reference there
were no major alterations in Pax-5 DNA binding in the
course of SK-BE(2)c differentiation. Thus, several neurob-
lastoma cell lines express both EBF proteins and Pax-5,
two genes known to induce expression of the mb-1 and
CD19 genes in pre-B cells, but neuroblastoma cells never-
theless fail to express these two target genes.
Pre-B lymphoma and neuroblastoma cell lines display 
differential expression of E-, Ets and ATF proteins
In addition to provide information of overall relation-
ships between different types of tumors, the micro-array
analysis also yield preliminary information about differ-
ential gene expression patterns of individual genes
(Appendix A). The data obtained in our experiments
Neuroblastoma cells express constitutive levels of Pax-5 proteins Figure 3
Neuroblastoma cells express constitutive levels of Pax-5 proteins.  Panel (A) display EMSAs where Oct or BSAP (Pax-5) bind-
ing sites was  incubated with nuclear extracts from Nalm6 (pre-B), KM3 (melanoma), SH-SY5Y  (neuroblastoma) and SK-N-
BE(2)c (neuroblastoma) cells.
Nalm6
Oct
BSAP
KM3 SH-SY5Y SK-N-BE(2)c
BSAP
BSAP
BSAP
Oct
Oct
Oct
Free probe
Oct
Pax-5
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Neuroblastoma cells express constitutive levels of Pax-5 proteins. Figure 4
Neuroblastoma cells express constitutive levels of Pax-5 proteins.  Panel (B) shows EMSA analysis of Pax-5 (BSAP) super-shift 
using nuclear  extracts from a set of neuroblastoma cell lines as indicated after addition  of either no, anti-Pax-5 or anti actin 
antibody. Panel (C) shows auto  radiogram with EMSAs using either a Pax-5 or an Oct binding site and nuclear  extracts from 
SK-N-BE(2)c (neuroblastoma) cells stimulated to undergo  differentiation with retinoic acid (RA) for the indicated times. The 
left  panel displays a super-shift experiment using either actin or Pax-5  antisera.  
Free probe
α α α α Actin
α α α α BSAP
Oct
α α α α Actin
α α α α BSAP
Oct
No antibody
No antibody
α α α α Actin
α α α α BSAP
Oct
No antibody
α α α α Actin
α α α α BSAP
Oct
No antibody
IMR-32 KCN-69n LA-N-1 SH-SY5Y
Pax-5
Oct
B
Oct BSAP
0 8 2 44 87 2 9 4 0 82 44 87 2 9 4
Free probe
(hr RA)
SK-N-BE(2)c
α α α α Actin
α α α α BSAP
Probe
Pax-5
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suggested differential expression of genes such as myb,
CBFβ and HMG 1, 3 and 4 proteins with high expression
restricted to the pre-B cells while Bcl-6 appeared to be
over-expressed specifically in neuroblastoma cells
(Appendix A). To further investigate other potential differ-
ences and similarities between pre-B and neuroblastoma
cells with regard to expression of gene regulatory proteins
we extracted expression data regarding additional genes
encoding transcription factors from our data set (Figure
4). This analysis indicated that even though the expres-
sion of several factors appeared similar, there were large
discrepancies in the mRNA expression of the E-protein
E47 and the ATF5 protein. These genes were expressed to
a high level in lymphoma cells but to a lower level in the
neuroblastoma cells. To investigate this further we ana-
lyzed the expression of E-proteins by EMSA using a bind-
ing site from the mouse Immunoglobulin heavy chain
intron enhancer as probe. This suggested that while one
prominent complex was formed in the pre-B cell lines, the
SK-N-BE(2)c cells did not contain any significant
amounts of µE5 binding activity (Figure 5A). Several com-
plexes were formed using nuclear extracts from SH-SY5Y
neuroblastoma cells, but the migration in the gel was dif-
ferent from that of the complexes observed in pre-B cells.
Investigating the µE5 binding activity in additional neu-
roblastoma cell lines suggested that nuclear extracts from
IMR-32 cells gave rise to a rapidly migrating complex
while extract from KCN-69n cells contained proteins
forming two different complexes. This suggests that there
might exist differences in E-protein expression in different
neuroblastoma cell lines.
To further investigate the E-box binding activities in SH-
SY5Y cells as compared to Nalm6 cells we performed
super-shift assays using antibodies against E2-2, E47 or c-
myc (Figure 5B). The major complexes formed by nuclear
extracts from the pre-B cell lines could be super-shifted
either by the addition of anti E2-2 or anti E47 antibody
while the complex formed in SH-SY5Y extracts reacted
only on the addition of anti E2-2 antisera. None of the
complexes in any of the cell lines were affected by the
addition of either the c-myc or the actin antibody. This
indicates that even though E2-2 is a major component in
the formation of µE5 binding activity in the pre-B cells, it
appears to form complex together with E47. This was not
seen in the SH-SY5Y cells suggesting that there exist a
Neuroblastoma cells and lymphoma cells display specific differences in transcription factor expression. Figure 5
Neuroblastoma cells and lymphoma cells display specific differences in transcription factor expression. The diagram shows the  
average expression levels of a set of transcription factors in the cell  lines analyzed by cDNA micro-arrays. The relative expres-
sion levels are  based on the comparison to a pooled human reference RNA.  
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distinct difference in the composition of E-box binding
complexes in the two cell types.
The micro-array analysis did also suggest a difference in
the expression of activator of transcription 5 (ATF5/ATF7/
ATFX) [25,26]. ATF5 is a transcription factor of the basic-
leucinezipper family that has been suggested to modulate
neurogenesis [27] making it potentially interesting in the
biology of the neuroblastoma cells. This protein binds to
c-AMP responsive element (CRE) [25,26] hence, we per-
formed EMSA analysis using oligonucleotide with a CRE
binding site and nuclear extracts from either pre-B cell
lines or neuroblastoma cells (Figure 6A). Both the pre-B
cells and the neuroblastoma cells generated two major
complexes (C1, C2) migrating with apparently the same
mobility as compared to the Oct proteins. The relative
abundance of these two complexes did however differ
since the pre-B cells contained larger relative amounts of
the slowly migrating complex (C1). This suggests that
there are differences in the expression of CRE binding pro-
teins in pre-B and neuroblastoma cells lines investigated.
EBF has also been suggested to share pre-B cell restricted
target genes with Ets proteins and one factor belonging to
this family of proteins suggested to contribute to B lineage
identity is the Ets protein Pu.1 [28,29]. In order to inves-
tigate the DNA binding activities in neuroblastoma and
pre-B lymphoma we incubated a PU.1 binding site (λB)
from the mouse Immunoglobulin λ enhancer with
nuclear extracts from the two cell types (Figure 7). This
showed a complex pattern of DNA binding activities but
only the pre-B cells contained a complex reacting to the
addition of anti Pu.1 anti-sera. Thus, we conclude, that
even though neuroblastoma and lymphoma co-express
several potent transcription factors there are also specific
differences. Thus, even though both cell types express EBF,
the protein would have to act in a different transcription
factor context in the two cell types.
Chromatin structure participates directly in the regulation 
of tissue specific gene expression patterns
These experiments suggested that there indeed are specific
differences in transcription factor expression between the
Neuroblastoma cells express variable levels of E-protein activity.  Figure 6
Neuroblastoma cells express variable levels of E-protein activity.  Panel (A) display auto radiograms with EMSAs of Oct and ?E-
5 (E-protein) DNA  binding activity in nuclear extracts from Nalm6 and KM3 pre-B lymphoma cells  and SH-SY5Y, SK-N-
BE(2)c, IMR-32, KCN-69n and LA-N-1 neuroblastoma cells.  
KM3 Nalm6 SH-SY5Y SK-N-BE(2)c
Free probe
Oct
Oct
Oct
Oct
E prot.
E prot.
E prot.
E prot.
IMR-32
Oct
E-prot.
KCN-69n
Oct
E-prot.
LA-N-1
Oct
E-prot.
SY
Oct
E-prot.
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two cell types, but also that they share expression of sev-
eral key regulatory molecules. This indicates that
additional components of gene regulation may be of cru-
cial importance for target gene selection. One potential
barrier to gene activation could be the chromatin struc-
ture, that is, the epigenetic setting of the cells directs the
transcription factors to their tissue specific target genes. To
investigate this possibility we analyzed the expression of
the mb-1 gene in neuroblastoma cells after disruption of
the chromatin structure by culturing the cells in the pres-
ence of the DNA de-methylating agent 5-azaC and the his-
tone deacetylase inhibitor TSA. RT-PCR analysis suggested
that while the untreated control cells did not express any
detectable amount of mb-1  transcripts the 5-azaC/TSA
treated cells expressed significant amounts of mb-1 tran-
scripts (Figure 7). To obtain an approximation of the
obtained expression levels we compared the amount of
mb-1 message in the treated neuroblastoma cells to that of
a serially diluted cDNA from Nalm6 pre-B cells. This sug-
gested that while the expression obtained in SK-N-BE(2)c
Neuroblastoma cells express variable levels of E-protein activity. Figure 7
Neuroblastoma cells express variable levels of E-protein activity.  Panel (B) show a EMSA analysis where nuclear extracts from 
either SH-SY5Y  neuroblastoma or Nalm6 pre-B lymphoma cells were pre-incubated with either  no antibody, anti E2-2, anti 
E47, anti myc or anti actin antibody as  indicated.  
SH-SY5Y
Free probe
α α α α E47
α α α α E2.2
No antibody
α α α α Actin
α α α α E47
α α α α E2.2
No antibody
α α α α Actin
Nalm6 B
α α α α myc
α α α α mycBMC Cancer 2004, 4:80 http://www.biomedcentral.com/1471-2407/4/80
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cells treated with 5-azaC/TSA was about one twentieth of
that observed in a pre-B cell, the SH-SY5Y cells were
induced to express levels comparable to that observed in
the pre-B cells. In contrast we were unable to observe an
induction of CD19 expression (Data not shown). Thus,
we conclude that the lineage specific regulation of the mb-
1 gene may be directly dependent on chromatin status,
while expression of other pre-B cell specific EBF target
genes, such as CD19, must be explained by other
mechanisms.
Discussion
We here report that neuroblastoma and pre-B lymphoma
cells share the expression of transcription factors believed
to be essential for normal B cell development while the
expression of their B lineage target genes remains tissue
specific. The finding that neuroblastoma cells expressed
Pax-5 was somewhat surprising even though this factor
has been shown to be involved in midbrain development.
Mice carrying a homologous disruption of the Pax-5 gene
lack both B-lymphoid cells and a fully developed central
nervous system [30,31]. In the B cell compartment it also
appears as if Pax-5 is crucial to lock the cell in the B-lym-
phoid developmental pathway. That is, even though pro-
B cells from Pax-5 deficient mice express a whole set of
early B cell markers [30,31], they can, in contrast to nor-
mal pro-B cells, be differentiated into other hematopoetic
lineages [32,33]. Thus, Pax-5 appears to be essential for
lineage fidelity in addition to be crucial for the comple-
tion of the B lymphoid development pathway. The former
has been attributed to an ability of Pax-5 to inhibit the
expression of cytokine receptors like M-CSF [32] and also
of Notch-1 [34]. Interestingly, Notch signaling plays a key
role in fate selection of neuronal cells and we have previ-
ously shown that over expression of a constitutively active
form of Notch-1 inhibits induced differentiation of neu-
roblastoma cells [23]. It is currently not clear whether a
link between Pax-5 and Notch1 expression is at hand in
neuronal cells, but it is noteworthy that neuroblastoma
cells express relatively high levels of Pax-5. Elevated
expression levels of Pax-5 has been detected in two other
tumors of neuronal origin, medulloblastoma [35] and
astrocytoma [36] and in vitro data [37] as well as observed
translocations in human B lineage tumors [38-40] indi-
cate that Pax-5 have oncogenic properties.
In contrast to the stable expression of Pax-5 there
appeared to be large differences in E-protein expression in
the neuroblastoma cell lines investigated. In neuronal tis-
sues a number of tissue specific bHLH proteins have been
defined. Importantly, these pro-neuronal bHLH proteins
require heterodimerization with E-proteins for the forma-
tion of DNA binding complexes. In the developing sym-
pathetic nervous system HASH-1 is transiently expressed
and is of pivotal importance for the formation of the auto-
nomic and olfactory nervous system, neuroendocrine
cells of the lung and specific regions of the telencephalon
(reviewed in [41]). We have previously shown that a
majority of the neuroblastomas express HASH-1, support-
ing the notion that the tumor is of embryonal origin [22].
We also showed that E2-2 is the preferential binding part-
ner of the pro-neuronal bHLH protein HASH-1 in SH-
SY5Y neuroblastoma cells [42], and the EMSA results pre-
sented in this paper, showing that E2-2 is the main E-pro-
tein binding a µE5-E-box, corroborate this observation.
Some findings indicate that E2-2 has specific and impor-
tant functions in neuronal tissues [43,44]. The gene is
expressed at substantial level in brain compared to most
other tissues [44] and E2-2 has been shown to bind and
regulate several neuronal/neuroendocrine promoters,
such as brain-specific FGF-1.B [44]. Several lines of inves-
tigation has suggested that E-proteins are redundant in B
cell development and that the apparent need of E2A pro-
tein in B cell development is due to lack of sufficient doses
of functional E-proteins [43,45]. This notion is substanti-
ated by the finding that E2A deficiency can be rescued by
expression of another E-protein, Heb [46], and that all
these proteins appear able to activate the pre-B cell
restricted λ5 promoter in synergy with EBF [47]. Thus,
based on these findings it is unlikely that the E-protein
composition would have any dramatic impact on EBFs
ability to activate target genes in neuroblastoma.
Our data also suggest that the chromatin structure of DNA
is able to modulate the function of transcription factors in
a dramatic manner. In the case of the mouse mb-1 pro-
moter is has been shown that methylation of specific C
residues in the promoter prevents the complex formation
between Pax-5 and Ets proteins, thereby reducing func-
tional activity of the promoter [48]. Both the Ets and Pax-
5 binding sites are conserved between mouse and human
and similar mechanisms acting on the human promoter
may well account for the observations in this report [49].
It is also noteworthy that we obtained a much higher level
of mb-1 transcription in the SH-SY5Y cells then in the SK-
N-BE(2)c cells (Figure 7), a finding that could be expected
due to that the SH-SY5Y cells expressed high levels of
BSAP and E-proteins while SK-N-BE(2)c cells appeared to
express somewhat lower levels of BSAP and no detectable
amounts of µE5 binding E-proteins (Figure 3A and 5A).
However, we were unable to observe any activation of
CD19  gene even after treatment with demethylating
agents suggesting that gene regulation is exerted at several
different levels or that the human CD19 gene is highly
dependent also of other factors, not present in the neurob-
lastoma cells. In this study we disrupt chromatin structure
by treating the cells with a combination of a methylation
inhibitor and a HDAC inhibitor. The processes of DNA
methylation and histone acetylation are intimately con-
nected. It has been known for a long time that histoneBMC Cancer 2004, 4:80 http://www.biomedcentral.com/1471-2407/4/80
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EBF target genes are expressed in a tissue specific manner Figure 8
Neuroblastoma and pre-B lymphoma differs in expression of CRE and Pu.1 site binding proteins. Panel (A) display EMSA analy-
sis of nuclear extracts from pre-B (KM3) or neuroblastoma cells (SH-SY5Y and SK-N-BE(2)c) incubated with a consensus 
cAMP responsive element (CRE). The two major complexes are denoted ATFC1 and ATFC2. Panel (B) show an EMSA analysis 
using nuclear extracts from either pre-B lymphoma cells (Nalm6) or the neuroblastoma cells SH-SY5Y and SK-N-BE(2)c, incu-
bated with a labelled Pu.1 binding site from the mouse Immunoglobulin l enhancer (lB). Ets1/2 or PU.1 antibody was included in 
the reactions as indicated. The arrow indicates the complex super-shifted by the anti PU.1 antibody.
ATFC1
ATFC2
KM3
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Oct
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Oct
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α α α α PU.1
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deacetylase inhibitors, by reactivating gene expression,
can inhibit growth and/or survival of cancer cells. Even
though the precise mechanisms behind the effect of these
drugs are largely unknown several of them are now
evaluated in clinical trials. Furthermore, the observations
of abnormal DNA methylation patterns in malignant cells
are becoming increasingly interesting, as new information
of the link between gene activation and methylation sta-
tus increase.
One dilemma, however, resides in the issue if a gene is
demethylated due to activation or activated due to
demethylation. In our specific case the latter would be the
most likely explanation. We cannot however exclude that
our observations are due to the induction of other
unknown proteins. The selective activation of mb-1 and
the presence of all the known crucial transcription factors
in the neuroblastoma cells would, however, be in line
with de-methylation being the primary event. The shared
expression of a whole set of transcription factors in such
diverse malignancies as lymphoma and neuroblastoma
may also be of importance for our view on the
relationships between different tumor types. That is, even
though these tumors are highly divergent and show large
differences in the clinical outcome, there may be genetic
links that can be used for drug targeting thus reducing the
complexity of cancer treatment dramatically.
Conclusion
These data suggest that transcription factors are able to
selectively activate target genes in different tissues and that
chromatin structure plays a key role in the regulation of
this activity.
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EBF target genes are expressed in a tissue specific manner Figure 9
Disruption of the chromatin structure allows for the activation of mb-1 transcription in neuroblastoma cells. (A) The top part 
of the figure shows ethidium bromide stained agarose gels with actin expression after RT-PCR analysis of Nalm6, SH-SY5Y and 
SK-N-BE(2)c cells without or after treatment with 5-azaC and TSA. Serial dilutions using 1, 1/5 and 1/25 of the template cDNA 
after 25 cycles of PCR were used. Panel (B) display auto-radiograms of southern blot analysis of mb-1 RT-PCR products 
obtained from untreated or 5-azaC/TSA treated SH-SY5Y and SK-N-BE(2)c cells and a serial dilution of untreated Nalm6 cells 
after 30 cycles of PCR as indicated.
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